The burgeoning UK environment surrounding psychedelics is increasingly nuanced, demanding careful navigation. While clinical research into compounds like psilocybin and copyright continues to unfold, and patient availability via private clinics is expanding, the policy framework remains ambiguous. This presents a unique situation for both individua